Pharmafile Logo

The risk of replicating social bias in synthetic patient data – The need for human intelligence partnered with AI

Authored by Paul Reed and Anabelle Gall

- PMLiVE

As we move forward in 2024, the healthcare industry has embraced the idea that AI-generated synthetic patients are here for the long haul. The remarkable ability to utilize artificial patients that mimic real-world patient data addresses crucial unmet needs, making it nearly impossible to envision a future healthcare industry without widespread usage and integration of synthetic patients.

However, we must strike a delicate balance between integrating AI tools into market research and acknowledging the invaluable role of human intelligence in understanding, verifying, supervising and analysing insights. In this article, we delve into the compelling arguments surrounding the opportunities and risks associated with the utilization of AI-generated synthetic patients in healthcare market research.

Read the full article here. 

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Quantitative specialist joins Research Partnership, London

Global healthcare market research consultancy Research Partnership has appointed Roy Rogers as a Quantitative Director in their UK offices in London

Webcast

Amplifying the patient voice: How to conduct patient research sensitively to uncover emotional insights

Webcast

The power of a good story: Turn your insights into effective storytelling with data visualisation

Article

How will COVID-19 affect uptake of vaccinations against other diseases?

Podcast

Living With Chronic Illness (Series one)

Webcast

China: How pharma can maximize success in this rapidly changing emerging market

Article

Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma

Infographic

Migraine market snapshot

Webcast

Monitoring the impact of COVID-19 on the market access landscape

Live webinar from Singapore

Digital #marcomms: How to evaluate and optimise marketing activities impacted by COVID-19